Denver, CO, United States of America

Michelle Kay Deaton


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2016-2017

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Michelle Kay Deaton: Innovator in Vaccine Development

Introduction

Michelle Kay Deaton is a prominent inventor based in Denver, CO (US). She has made significant contributions to the field of vaccine development, particularly in the area of genetically modified viruses. With a total of 2 patents, her work focuses on creating effective live vaccine agents for serious viral infections.

Latest Patents

Michelle's latest patents include an attenuated live vaccine for the Crimean-Congo hemorrhagic fever virus and Erve virus. The genetically modified nairoviruses in this invention possess a viral ovarian tumor protease with a decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment. Another significant patent is the Crimean-Congo hemorrhagic fever virus vaccine, which similarly utilizes a genetically modified hemorrhagic fever virus to create a safe and effective vaccine.

Career Highlights

Throughout her career, Michelle has worked with esteemed organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and Colorado Seminary, which owns and operates the University of Denver. Her experience in these institutions has allowed her to advance her research and contribute to public health.

Collaborations

Michelle has collaborated with notable colleagues, including Eric Bergeron and Scott Dusan Pegan. These partnerships have further enriched her research and innovation in vaccine development.

Conclusion

Michelle Kay Deaton is a trailblazer in the field of vaccine innovation, with her work paving the way for new treatments against viral infections. Her contributions are vital to advancing public health and enhancing vaccine efficacy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…